Misplaced Pages

WAY-317538

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Redirected from WAY-317,538) Chemical compound Pharmaceutical compound
WAY-317538
Legal status
Legal status
  • In general: legal
Identifiers
IUPAC name
  • 5-Morpholin-4-yl-pentanoic acid (4-pyridin-3-yl-phenyl)-amide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H25N3O2
Molar mass339.439 g·mol
3D model (JSmol)
SMILES
  • C3COCCN3CCCCC(=O)Nc1ccc(cc1)-c2cccnc2

  • HCl: C1COCCN1CCCCC(=O)NC2=CC=C(C=C2)C3=CN=CC=C3.Cl
InChI
  • InChI=1S/C20H25N3O2/c24-20(5-1-2-11-23-12-14-25-15-13-23)22-19-8-6-17(7-9-19)18-4-3-10-21-16-18/h3-4,6-10,16H,1-2,5,11-15H2,(H,22,24)
  • Key:XCHIZTUBUXZESJ-UHFFFAOYSA-N

  • HCl: InChI=1S/C20H25N3O2.ClH/c24-20(5-1-2-11-23-12-14-25-15-13-23)22-19-8-6-17(7-9-19)18-4-3-10-21-16-18;/h3-4,6-10,16H,1-2,5,11-15H2,(H,22,24);1H
  • Key:GBMDUJQQSGOIFW-UHFFFAOYSA-N
  (what is this?)  (verify)

WAY-317538 (SEN-12333) is a drug that acts as a potent and selective full agonist for the α7 subtype of neural nicotinic acetylcholine receptors. It was not the most potent compound in the series, but was selected for further development on the basis of its high selectivity over related receptors, ease of synthesis, and good in vivo properties including high oral bioavailability and good brain penetration. It has nootropic and neuroprotective effects in animal studies, and is being investigated as a potential treatment for neurodegenerative and neurocognitive conditions including Alzheimer's disease and schizophrenia.

References

  1. Haydar SN, Ghiron C, Bettinetti L, Bothmann H, Comery TA, Dunlop J, et al. (July 2009). "SAR and biological evaluation of SEN12333/WAY-317538: Novel alpha 7 nicotinic acetylcholine receptor agonist". Bioorganic & Medicinal Chemistry. 17 (14): 5247–58. doi:10.1016/j.bmc.2009.05.040. PMID 19515567.
  2. Roncarati R, Scali C, Comery TA, Grauer SM, Aschmi S, Bothmann H, et al. (May 2009). "Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders". The Journal of Pharmacology and Experimental Therapeutics. 329 (2): 459–68. doi:10.1124/jpet.108.150094. PMID 19223665. S2CID 6667145.
Stimulants
Adamantanes
Adenosine antagonists
Alkylamines
Ampakines
Arylcyclohexylamines
Benzazepines
Cathinones
Cholinergics
Convulsants
Eugeroics
Oxazolines
Phenethylamines
Phenylmorpholines
Piperazines
Piperidines
Pyrrolidines
Racetams
Tropanes
Tryptamines
Others
ATC code: N06B
Nicotinic acetylcholine receptor modulators
nAChRsTooltip Nicotinic acetylcholine receptors
Agonists
(and PAMsTooltip positive allosteric modulators)
Antagonists
(and NAMsTooltip negative allosteric modulators)
Precursors
(and prodrugs)
See also
Receptor/signaling modulators
Muscarinic acetylcholine receptor modulators
Acetylcholine metabolism/transport modulators


Stub icon

This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it.

Categories: